Search results for "prostate"

LYCOPENE AND PROSTATE CANCER: AN OVERVIEW

2018

Prostate cancer is one of the most common cancers in the world. Its pathogenesis is multifactorial and is linked to risk factors such as age, diet, cigarette smoking, family history and the onset of oxidative stress. In recent times, therefore, we are investigating the use of antioxidants as a primary and tertuary prevention of prostate cancer. Numerous studies in the literature focused on lycopene, a molecule belonging to the family of carotenoids that is commonly foud in tomatoes and products derived from it. The literature analyzed in the last two years shows how lycopene inhibits different mecchanism linked to carcinogenesis and tumor progression. However, there are still many points to…

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study.

2003

OBJECTIVE: To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS: From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2-4N0-3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS: Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an object…

Short and mid-term Functional Outcomes after High-intensity Ultrasound (HiFu) in the treatment of patients with localized advanced prostate cancer

2010

Vīriešu līdzestība prostatas vēža skrīningā

2019

Onkoloģisko slimību skaits ar katru gadu pieaug, tāpēc agrīnai diagnosticēšanai ir liela nozīme. Bakalaura darba tēma „Vīriešu līdzestība prostatas vēža skrīningā”. Pētījuma aktualitāti noteica statistiski apstiprināts fakts, ka prostatas vēzis ir viens no izplatītākajām onkoloģiskām slimībām Latvijā vīriešu vidū. Hipotēze: Vīriešu līdzestība prostatas vēža skrīningā būtiski ietekmē agrīnu slimības diagnosticēšanu. Darba mērķis: Noskaidrot vīriešu līdzestību prostatas vēža skrīninga programmas ietvaros. Pētījuma veikšanai izmantota kvantitatīvā pētniecības metode. Pētījuma instruments – anketa. Pētījuma rezultāti liecina, ka lielākā daļa respondentu (88%) izprot savlaicīgu diagnosticēšanas …

Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

2021

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…

Characterization of the metabolic profile and identification of potential therapeutic targets in advanced prostate cancer patients

2023

INTRODUCCIÓN El cáncer de próstata (CaP) representa el segundo tumor en incidencia en hombres y es la quinta causa de muerte por cáncer a nivel global. El CaP es un tumor hormono-dependiente, que requiere de la activación del receptor de andrógenos (AR) para su proliferación. Clínicamente, se caracteriza por una gran variabilidad en su evolución, progresando desde una condición indolente hasta un fenotipo agresivo que puede diseminarse y metastatizar a los nodos linfáticos y huesos. Actualmente, el diagnóstico temprano del CaP se realiza mediante la determinación sérica del antígeno prostático específico (PSA) y el examen rectal digital (DRE). Si estas pruebas dan resultados anómalos y hay …

I-125 seed calibration using the SeedSelectron(®) afterloader: a practical solution to fulfill AAPM-ESTRO recommendations.

2012

Purpose SeedSelectron® v1.26b (Nucletron BV, The Netherlands) is an afterloader system used in prostate interstitial permanent brachytherapy with I-125 selectSeed seeds. It contains a diode array to assay all implanted seeds. Only one or two seeds can be extracted during the surgical procedure and assayed using a well chamber to check the manufacturer air-kerma strength (SK) and to calibrate the diode array. Therefore, it is not feasible to assay 5–10% seeds as required by the AAPM-ESTRO. In this study, we present a practical solution of the SeedSelectron® users to fulfill the AAPM- ESTRO recommendations. Material and methods The method is based on: a) the SourceCheck® well ionization chamb…

A Shape-based Statistical Method to Retrieve 2D TRUS-MR Slice Correspondence for Prostate Biopsy

2012

International audience; This paper presents a method based on shape-context and statistical measures to match interventional 2D Trans Rectal Ultrasound (TRUS) slice during prostate biopsy to a 2D Magnetic Resonance (MR) slice of a pre-acquired prostate volume. Accurate biopsy tissue sampling requires translation of the MR slice information on the TRUS guided biopsy slice. However, this translation or fusion requires the knowledge of the spatial position of the TRUS slice and this is only possible with the use of an electro-magnetic (EM) tracker attached to the TRUS probe. Since, the use of EM tracker is not common in clinical practice and 3D TRUS is not used during biopsy, we propose to per…

Trattamento dell'incontinenza urinaria post-prostatectomia di grado severo mediante l'uso di sling tipo "AdVance"

2011

Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid

2007

Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is a rare complication whose incidence rate has climbed in recent years. ONJ is defined as an unexpected development of necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate and Zoledronate. Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also o…